Press Releases

LONDON, 10 Jun. 2024 (GLOBE NEWSWIRE) -- This is the Start of Day Message for GlobeNewswire.

GlobeNewswire is operated by Notified and is designated by the FCA as an approved primary information provider.

Disclaimer

The content and accuracy of all information distributed through Notified is wholly the responsibility of the originator. Notified accepts no liability for any losses arising from reliance by any person upon the content of any announcement.

If you... (continue reading...)

ROTTERDAM, The Netherlands (10 June 2024) – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today announces that IMCD Italy has signed an agreement to acquire 100% of the shares in Selechimica S.R.L. (“Selechimica”), an Italian distributor in the pharmaceutical industry.

Headquartered in Milan, Italy, Selechimica distributes an extensive portfolio of Active Pharmaceutical Ingredients (APIs). With 3 employees, Selechimica... (continue reading...)

Pratteln, Switzerland, June 10, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that its partner Sperogenix Therapeutics has launched a paid-for Early Access Program (EAP) for AGAMREE® (vamorolone) in China for patients with Duchenne muscular dystrophy (DMD).

In April 2024, the Hainan Medical Products Administration (HMPA) authorized the EAP for AGAMREE based on local policies, AGAMREE’s existing overseas approvals (U.S., EU, UK) and its demonstrated ability to... (continue reading...)

Corbion hereby reports the transaction details related to its € 20 million share buyback program announced on 26 April 2024.

During the week of 3 June up to and including 7 June 2024 a total of 110,083 shares were repurchased at an average price of €20.1621 for a total amount of €2,219,505.58.

To date, the total consideration for shares repurchased amounts to €10,802,105.47 representing 54.01% of the overall share buyback program.

Corbion publishes on a weekly... (continue reading...)

European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer

• Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive resected non-small cell lung cancer, as demonstrated in the Phase III ALINA study1
• Alecensa’s approval addresses an urgent unmet need in the early-stage setting where about half of all people experience disease... (continue reading...)